Design considerations of an IL13Rα2 antibody–drug conjugate for diffuse intrinsic pontine glioma

Diffuse intrinsic pontine glioma (DIPG), a rare pediatric brain tumor, afflicts approximately 350 new patients each year in the United States. DIPG is noted for its lethality, as fewer than 1% of patients survive to five years. Multiple clinical trials involving chemotherapy, radiotherapy, and/or targeted therapy have all failed to improve clinical outcomes. Recently, high-throughput sequencing of a cohort of DIPG samples identified potential therapeutic targets, including interleukin 13 receptor subunit alpha 2 (IL13Rα2) which was expressed in multiple tumor samples and comparably absent in normal brain tissue, identifying IL13Rα2 as a potential therapeutic target in DIPG. In this work, we investigated the role of IL13Rα2 signaling in progression and invasion of DIPG and viability of IL13Rα2 as a therapeutic target through the use of immunoconjugate agents. We discovered that IL13Rα2 stimulation via canonical ligands demonstrates minimal impact on both the cellular proliferation and cellular invasion of DIPG cells, suggesting IL13Rα2 signaling is non-essential for DIPG progression in vitro. However, exposure to an anti-IL13Rα2 antibody–drug conjugate demonstrated potent pharmacological response in DIPG cell models both in vitro and ex ovo in a manner strongly associated with IL13Rα2 expression, supporting the potential use of targeting IL13Rα2 as a DIPG therapy. However, the tested ADC was effective in most but not all cell models, thus selection of the optimal payload will be essential for clinical translation of an anti-IL13Rα2 ADC for DIPG. Supplementary Information The online version contains supplementary material available at 10.1186/s40478-021-01184-9.


Introduction
Approximately 350 children per year in the United States are diagnosed with the high-grade glioma (HGG) subtype denoted diffuse intrinsic pontine glioma (DIPG), which represents 16% of all pediatric and young adult central nervous system tumors [17,22,52]. The prognosis for DIPG patients is dire, with median survival lingering under 1 year and fewer than 1% of DIPG patients surviving to 5 years [50]. DIPG presents in the pons region of the midbrain as tumor nodules interwoven amongst normal tissue, making surgical removal impossible [40].
After initiation, DIPG cells disseminate and can invade into multiple brain regions and even into the spinal cord [12,46]. Standard clinical care for DIPG consists of 54-60 Gy local field radiotherapy dosed over 6 weeks which temporarily improves patient neurological function and extends survival by 2-3 months [45], although resulting in lower quality of life due to negative long-term effects of radiation on pediatric brain function and development [8]. Despite investigation of multiple regimens based on chemotherapy, radiotherapy or next-generation targeted therapeutic agents, outcomes for DIPG remain essentially unchanged resulting in a disease marred by minimal long-term survivorship desperately in need of new targets and therapeutics [9,14,18,20,21,27,29,38]. Given the marginal advances in clinical outcomes for DIPG, recent efforts to improve translational research have focused on high-throughput sequencing of available cohorts of patient-derived DIPG tissue samples which resulted in discovery of new targets for therapeutic intervention, including interleukin 13 receptor subunit alpha 2 (IL13Rα2) [7].
IL13Rα2 is a cell-surface protein involved in regulation of interleukin 13 (IL-13) and interleukin 4 (IL-4) signaling [15]. IL13Rα2 directly binds IL-13 as a monomer to induce IL13RA2 signaling [23], and IL13Rα2 shows four orders-of-magnitude greater binding affinity for IL-13 than the alpha 1 receptor subunit (IL13Rα1) [37]. Conversely, IL13RA2 is capable of associating with and regulating response of IL-4 only by acting in concert with IL-4R [2]. IL13Rα2 signaling has been studied in the context of multiple diseases: IL13Rα2 activates the focal adhesion kinase (FAK, also called PTK2) and phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K) pathways through the family with sequence similarity 120A (FAM120A) scaffold protein [5] which mediates invasion and metastasis in colon cancer, IL-13 stimulation of IL13Rα2 activates Transforming Growth Factor Beta 1 (TGFβ1) and induces allograft fibrosis [19], and IL13Rα2 cooperates with epidermal growth factor receptor vIII (EGFRvIII) to promote the growth of glioblastoma multiforme (GBM) [43]. IL13Rα2 has previously been identified as a target of interest in numerous cancers, including malignant gliomas [28,30,51], pancreatic cancer [23], melanoma [44], ovarian cancer [32], and colon cancer [5]. IL13Rα2 has been explored clinically as both a CAR-T cell based therapy and as a phase III recombinant protein immunoconjugate target trial for adult glioma with promising outcomes [10,11,33,34], supporting further investigation of immunotherapies or immunoconjugate therapies targeting IL13Rα2 in other diseases with appropriate receptor expression patterns.
Antibody-drug conjugates (ADCs) are a novel class of immunoconjugate therapeutics which chemically link protein-specific antibodies with potent cytotoxic agents to target antigen-expressing cells with high specificity. Recently, FDA approved ADCs such as trastuzumab emtansine, trastuzumab emtansine [6], inotuzumab ozogamicin [31], and polatuzumab vedotin [49] are regarded as breakthrough therapeutics for breast cancer, Hodgkin's lymphoma, and acute lymphoblastic leukemia respectively, which subsequently resulted in initiation of numerous ADC-based clinical trials. Foremost among design considerations for new ADCs is identifying the cell surface antigen target for the ADC, which requires both differentially elevated expression of the antigen target in tumor cells and internalization then degradation of the conjugated antibody to release the chemically-bound cytotoxic molecules [35].
In the context of DIPG, previous high-throughput transcriptome sequencing identified IL13Rα2 as a DIPG-selective genetic target versus patient-derived normal brain tissue samples (17.32-fold overexpression, p = 0.0003) [7] and immunohistochemical (IHC) staining demonstrated 12/17 samples (70.5%) were positive for IL13Rα2 of which 6/12 (50.0%) showed medium or strong expression [7]. Similar expression patterns of IL13Rα2 in DIPG and normal brain tissue have recently been independently confirmed [56]. Overexpression of IL13Rα2 cell surface protein in cancerous cells and relative absence in normal tissue meets the first criteria of ADC design consideration and demonstrated internalization and degradation of both IL-13 and anti-IL13Rα2 antibody through IL13Rα2 receptor binding [5,10,11,16,33,34] meets the second criteria, suggesting an anti-IL13Rα2 ADC may be a viable therapy for DIPG.
In this manuscript, we investigate the role of IL13RA2 in growth of DIPG and validate the potential of an anti-IL13Rα2 antibody-drug conjugate as a potential novel treatment for DIPG. The studies presented here demonstrate that direct stimulation of IL13Rα2 through canonical ligands induces minimal effect on either cellular proliferation or cellular invasion of DIPG cells. Conversely, cell viability assays demonstrate strong association between elevated IL13Rα2 expression and sensitivity to anti-IL13Rα2 ADC agents, affirming the potential of IL13Rα2 as a therapeutic target in DIPG.
Additional details for cell models used in this study, including IL13Rα2 expression status, are provided in Table 1. The human alveolar rhabdomyosarcoma cell line RH30 (accession ID CVCL_0041) was used solely for a supplemental experiment to validate the recombinant IL-4 and IL-13 proteins used in this study. RH30 was cultured in Roswell Park Memorial Institute (RPMI) 1640 Medium (Cat #12633012; Thermo Fisher Scientific) supplemented with 1% P/S and 10% FBS. All cell lines were tested for authenticity at their institute of origin and were additionally authenticated at initiation of study via short tandem repeat (STR) fingerprinting (Additional file 3: Table 1) performed by the University of Arizona Genetics Core, as well as being surveyed for changes to proliferation, morphology, or behavior.

Immunoblotting
Cells for immunoblotting were lysed in RIPA lysis and extraction buffer (Cat #89901; Thermo Fisher Scientific) supplemented with HALT protease and phosphatase inhibitor cocktail (Cat #78440; Thermo Fisher Scientific) following the manufacturer's protocol. Collected  [25] 28823557 [47] 28823557 [47] 23603901 [13] 22120608 [54] protein lysates were stored at -80 °C. 20 µg of protein was loaded into the channel of an SDS-polyacrylamide gel electrophoresis (PAGE) gel, one channel per cell model. Electrophoresis-separated proteins were electrically transferred to PVDF membrane, washed in TBST buffer, and blocked in 5% fat-free milk for 2 h at room temperature, then incubated with primary antibodies at 4 °C overnight. Following primary antibody blocking, specific signal was detected with species-appropriate horseradish peroxidase-conjugated secondary antibody using Clarity Western blot ECL Substrate (Cat #1705061; Bio-Rad Laboratories, Hercules, CA, USA) and imaged using an IVIS Lumina II imaging system (Caliper Life Sciences, Hopkinton, MA, USA).
Western blot studies were completed in triplicate to ensure validity of protein expression trends.
All stimulation experiments were performed with in triplicate for each treatment condition, with each experiment performed with three technical replicates for each cell model.

IL-4 and IL-13 recombinant protein validation studies
RH30 cells were plated in 6 cm plates and serum starved overnight in RPMI-1640 media with 1% P/S. Cells were then exposed for 60 min to 20 ng/mL recombinant IL-4 in RPMI-1640 + 1% P/S, 20 ng/mL recombinant IL-13 in RPMI-1640 + 1% P/S, or RPMI-1640 + 1% P/S (control). Cells were then harvested as described in the Immunoblotting section and probed for overall STAT6 level and phosphor-STAT6 level to confirm phosphorylation of STAT6 following IL-4 or IL-13 exposure, similar to a previously published study [26]. Validation stimulation experiments were performed in triplicate for each treatment condition.
The inserts were removed, aspirated, washed with twice with H 2 O and PBS, and the inside of the inserts were swabbed to remove non-invasive cells. Remaining cells were fixed with 4% paraformaldehyde (PFA) for 20 min then washed with PBS and DDH 2 O. Fixed cells were stained with 0.1% crystal violet in 10% methanol for 20 min, washed twice with DDH 2 O, then allowed to dry overnight. Fixed, dried inserts were treated with 250 µL of 10% acetic acid and then crystal violet intensity was quantified using a BioTek Synergy HT plate reader at 595 nm read wavelength. Cell invasion was plotted in GraphPad Prism.
All invasion experiments were performed in triplicate for each treatment condition, with each experiment performed with three technical replicates for each cell model.
All cell viability experiments were performed in triplicate for each treatment condition, with each experiment performed with three technical replicates for each cell model.

Antibody Conjugations
Antibody conjugation was performed by Moradec, LLC. IL13Rα2 2E10 antibody was concentrated to approximately 2 mg/mL. 0.1 mL of concentrated antibody was used for initial conjugation optimizations to reach drugantibody ratio (DAR) around 3-4, then the remaining antibody was used to carry out the conjugation with maleimide-valine-alanine-Pyrrolobenzodiazepine (Mal-VA-PBD). The conjugation was a maleimide-cysteine based method by first reducing the antibody inter-chain disulfide bonds with TCEP and then linking the maleimide moiety of the drug to the reduced cysteines to generate the ADC. The conjugated ADC was desalted on Sephadex G50 columns to remove residual unreactive toxins and then buffer exchanged pH 7.2 in PBS. The final DAR was calculated from the A333nm:A280nm ratio and was determined to be 3.36 for anti-IL13Rα2::PBD.
All cell viability experiments were performed in triplicate for each treatment condition, with each experiment performed with three technical replicates for each cell model.

Antibody-drug conjugate ex ovo cell viability studies
Fertilized Coturnix japonica (Japanese quail) eggs were purchased from Boyd's Bird Company (Eagle Creek, OR, USA) and Purely Poultry (Fremont, WI, USA), stored at 4 °C for 120 h, and then incubated at 37 °C and 70% humidity for approximately 54 h in an egg incubator. Quail eggs were opened by our mechanical device [48] into six-well plates (Cat # CC Plate-PS-6A-F-C-S; Advangene, Lake Bluff, IL, USA), then incubated for 112 h (embryonic day 7) at which point unfertilized/nonviable quail were removed.
The chorioallantoic membrane (CAM) of viable quails were superficial injured by carefully placing and carefully removing an Eppendorf tube lid against the CAM. The mesh tumor modules were placed on the injury site and incubated for 120 h. Add the end of the incubation, 100 µl of PBS containing 1.5 mg of luciferin-d (Cat #122799; PerkinElmer, Waltham, MA, USA) was added to the tumor modules, incubated in the dark for 5 min, and resulting bioluminescence was measured using an IVIS Lumina (PerkinElmer). The quail were imaged with a 15 s exposure for total light emission. Total light emission amongst ADC treatment concentrations were normalized to control emission to determine final SF-8268 cell viability.

Statistics
Dunnett's multiple comparisons test performed in GraphPad Prism was used to analyze statistical differences in cytokine stimulation cell proliferation assays and in cytokine stimulation cell invasion assays. Testing for linear trend was performed in GraphPad Prism to determine if cell proliferation by cytokine stimulation occurred in a dose-dependent manner.

IL13Rα2 is expressed in DIPG tumor samples and cell models
We expanded the cohort of sequenced DIPG transcriptomes by incorporating newly-published RNA sequencing data from ten (10) DIPG tumor samples and two (2) normal pons tissue samples [41]. Evaluation of the expanded cohort confirmed the status of IL13Rα2 overexpression, with the combined new dataset and previous dataset (n = 28 DIPG tumor samples, n = 18 normal tissue samples) demonstrating 21-fold overexpression in matched tumor vs. normal brain tissue and 12-fold overexpression in all tumor vs. normal samples (p < 0.0001) (Fig. 1a, b), remaining significantly higher (p = 0.01) than  (Fig. 1b,  c).
Subsequently, available DIPG cell models were assayed for protein-level expression of IL13Rα2 to determine optimal models for further in vitro investigation. A list of cell models used in this study are provided in Table 1. Several cell models show strong IL13Rα2 expression, including CHLA-200, DIPG-6, DIPG-13, DIPG-17, and SF-8628 (Fig. 1d), while DIPG-24 shows notably lower (but not absent) IL13Rα2 expression.

Functional impact of IL13Rα2 in DIPG growth and invasion
Given the overexpression of IL13Rα2 and the importance of the receptor in other diseases, we first investigated the role of IL13RA2 signaling in DIPG. To determine if cytokine stimulation modifies cell growth in vitro, cells were serum-or supplement-starved for 24 h then treated with varying concentrations of the known cytokine binding partners of IL13Rα2, IL-4 and IL-13 ( Fig. 2a-d). Of the cell model-cytokine combinations tested, only SF-8628 stimulated with IL-13 demonstrated any significant increase in cell growth versus starvation media as the negative control (Fig. 2b). Notably, the increased cell growth from IL-13 stimulation of SF-8628 was statistically dose-dependent (slope = 0.0215, p < 0.0001). All other combinations demonstrated no statistically significant change in cell viability (Fig. 2a, c, d). Lack of DIPG-24 response is consistent with the lower expression of IL13Rα2 in the assayed cell models, as DIPG-24 has reduced expression compared to SF-8628. However, no cell model showed increase in growth comparable to standard growth media (+ CTRL). While IL-13 may impact growth rate of a single cell model the effect is negligible compared to optimal growth conditions, and IL-4 demonstrated no significant impact on growth. We confirmed expected mechanistic activity of the IL-4 and IL-13 recombinant proteins by replicating a previously published study [26] (Additional file 2: Fig. 2).
Development of new DIPG tumor nodules both within the pons and throughout the CNS is critical to disease progression and mortality, thus we also investigated the effect of IL-13 stimulation on the invasive potential of DIPG/GBM cell models. As IL13Rα2 is significantly more selective for IL-13 and because IL-13 demonstrated a modest but statistically significant impact on growth versus starvation media, we focused on the impact of IL-13 on cellular invasion [37]. We assayed two IL13Rα2-high cell models (SF-8628 and CHLA-200) and one IL13Rα2-low cell model (DIPG-24) to determine if IL-13 stimulation impacted cellular invasion in a dose-dependent manner (Fig. 2e-g).
Neither the IL13Rα2-high nor IL13Rα2-low cell models showed any statistically significant change in cell invasion following IL-13 stimulation versus negative control. Conversely, cells treated with standard growth media (+ CTRL) demonstrated a statistically significant increase in invasion, showing the propensity for the cell models to invade in proper conditions.

Pharmacological testing of IL13Rα2-targeting therapeutics in DIPG
Having determined that exposure to canonical IL13Rα2 ligands resulted in minimal impact on cell proliferation and invasion, we investigated the pharmacological response of DIPG/GBM cell models to IL13Rα2 antibody-based agents. As a first-pass proof-of-concept experiment, we used a primary antibody + secondary antibody::cytotoxic agent system to test if IL13Rα2 expression conferred sensitivity to IL13Rα2 targeting agents. We selected four DIPG cell models and one GBM cell model (Table 1) for the proof-of-concept experiments. Cells were exposed to fixed concentrations of IL13Rα2 2E10 primary antibody in combination with varying concentrations of a secondary antibody conjugated to duocarmycin, a potent cytotoxic agent commonly conjugated to ADCs (Additional file 1: Fig. 1a). While the results did not show a direct relationship between IL13Rα2 expression and duocarmycin sensitivity, two models showed stronger response (SF-8628 and CHLA-200), demonstrating that IL13Rα2 expression can confer sensitivity to antibody-based therapies.
We theorized that the inability of IL13Ra2 antibodymediated cytotoxin delivery to decrease cell viability in some models was due to failure of duocarmycin to overcome innate chemoresistance of most DIPG cell models. To interrogate this possibility, we selected a IL13Ra2-high and one IL13Ra2-low cell model (SF-8628 and DIPG-24, respectively) and treated them with two commonly used and readily accessible ADC payloads, DM-1 (also called mertansine) and monomethyl auristatin F (MMAF). SF-8628 was sensitive to both MMAF (IC 50 = 3.84 µM, Additional file 1: Fig. 1b) and DM-1 (IC 50 = 82.5 nM, Additional file 1: Fig. 1c), while DIPG-24 showed negligible sensitivity to (MMAF, Additional file 1: Fig. 1b) and slight sensitivity to DM-1 (Additional file 1: Fig. 1c). Disparity in cellular response to potent single agent cytotoxics suggests that selection of the payload agent may be critical for the effectiveness of any ADC developed to eliminate DIPG cells.
Partially positive results from the proof-of-concept experiments supported the continued evaluation of IL13Rα2 as a target for ADC therapies in DIPG; thus, we developed a fully conjugated antibody::cytotoxic agent for experimental validation. As previously mentioned, a critical challenge of DIPG treatment is the clinicallydemonstrated resistance to most standard chemotherapeutic agents and the failure of most clinical trials [9,14,18,20,21,27,29,38], also reflected in the varied efficacy of the ADC cytotoxic agents tested on the DIPG cell models (Additional file 1: Fig. 1b, c). Thus, we selected pyrrolobenzodiazepine (PBD) as the payload for the IL13Rα2 ADC as PBD is known to promote cell death in model systems often resistant to standard chemotherapy agents or standard ADC cytotoxic payloads [39].
We validated the activity of the anti-IL13Rα2::PBD ADC using the same cell models used in previous experiments (Table 1). Results from the cell viability assays demonstrate that three of four IL13Rα2-positive cell models (CHLA-200, DIPG-17, and SF-8628) were highly sensitive to anti-IL13Rα2::PBD, with all three cell models reaching 50% cell viability below 100 ng/mL ADC concentration and under 10% cell viability at highest tested ADC concentrations (Fig. 3a). One IL13Rα2high cell model showed lesser response to the ADC (DIPG-6, IC 50 = 2.27 µg/mL), which could potentially be attributed to DIPG-6 often demonstrating resistance to many agents [25]. The IL13Rα2-low cell model also demonstrated lesser response to the ADC (DIPG-24, IC 50 = 3.32 µg/mL) consistent with the lower (but not absent) expression of IL13Rα2.
Finally, we tested the efficacy of the anti-IL13Rα2::PBD ADC in a luciferase/RFP-expressing SF-8628 quail ex ovo xenograft, with the ADC again showing strong response and a clear dose-dependent response (IC 50 = 0.59 µg/mL) in the immunoprivileged ex ovo model system (Fig. 3b). Overall, anti-IL13Rα2::PBD drug response associates well (4/5 models tested) with IL13Rα2 expression in DIPG and positive response successfully translates to an ex ovo xenograft system.

Discussion
Relatively few treatments exist for DIPG, with the majority of clinical trials having demonstrated little to no improvement in clinical outcomes. Previous investigations of IL13Rα2 as a therapeutic target by various treatment modalities [10,11,33,34] suggest the utility of IL13Rα2 targeting in the context of an immunotherapy or immunoconjugate for multiple diseases, including DIPG. However, overall clinical experience using CAR-T cell therapy in brain tumors has identified barriers to advancement. Specifically, the milieu of immune inflammatory responses to CAR-T cell therapy (termed CAR T-related encephalopathy syndrome, CRES) are often life-threatening toxicities [1]. While ADC therapies can also potentially illicit immunogenic responses, clinical use of bevacizumab monoclonal antibody therapy in glioblastoma has demonstrated a reduced need for corticosteroids as a consequence of treatment [24] suggesting monoclonal antibodies (and by extension ADC agents) may have lessened immunogenicity in brain tumors compared to CAR-T cell therapy. Additionally, brain tumor microenvironments are frequently immunosuppressive [1], which may be less challenging to an ADC operating through cytotoxicity-induced apoptosis compared to CAR-T cell therapy which requires immune cell involvement.
From our studies, three key points can be taken from the exploration of IL13Rα2 as a therapeutic target in DIPG. First, stimulation by both IL13Rα2 cytokine binding partners (IL-4 and especially the canonical ligand IL-13) demonstrate negligible effect on cell proliferation or invasion, suggesting that IL13Rα2 binding and signaling may not be essential to DIPG progression, thus even inadvertent stimulation of this pathway through the use of an ADC is unlikely to negatively impact the course of treatment. Second, high expression of IL13Rα2 in DIPG and GBM associates strongly with sensitivity to anti-IL13Rα2::PBD ADC, although PBD may have limitations in killing more resistant DIPG cell models as PBD acts through inducing DNA damage [55]. Finally, as anti-IL13Rα2::PBD demonstrates efficacy in most but not all DIPG models, the selection of the cytotoxic payload will be critical for the success of any ADC developed for DIPG.
The negligible impact on either cell proliferation or invasion is somewhat surprising, given previous studies demonstrating IL13RA2 acting as a strong mediator of both proliferation and invasion in multiple diseases [4,23,43]. In glioblastoma, IL13RA2 has been shown to cooperate with mutant EGFRvIII to mediate growth [43], while EGFR mutations including EGFRvIII are believed to not be widely recurrent in DIPG [25,53] which may limit the importance of IL13RA2 in DIPG progression. Additionally, a separate study performed in our laboratory explored the effect of multiple receptor-ligand pairs highly expressed in DIPG and known to impact proliferation in other disease, with the majority of canonical signaling pairs demonstrating similarly limited impact on DIPG cell proliferation and invasion (manuscript in preparation).
Despite the positive correlation between anti-IL13Rα2::PBD ADC sensitivity and IL13Rα2 expression status, DIPG-6 insensitivity to the ADC exemplifies the key challenge in designing ADC therapeutics for DIPG. A key requirement in the design of a clinical ADC is selecting an exceedingly potent cytotoxic capable of affecting cellular death at low (~ 10 nM) concentrations, as ADC efficacy is heavily linked to payload efficacy [42]. While the innate chemoresistance of DIPG may be somewhat abrogated by PBD's ability to overcome chemoresistance, PBD still operates via DNA damage mechanisms similar to duocarmycin [55] and thus selecting a non-standard ADC payload may potentially overcome the resistance seen in DIPG-6 and potentially other DIPG cell models.
Nonetheless, the promising proof-of-concept results of anti-IL13Rα2::PBD ADC in DIPG present a translational opportunity. There are currently no clinicallyvalidated therapeutics available for DIPG, nor are there any FDA approved IL13Rα2 immunoconjugate agents. Successful translation of an IL13Rα2 ADC for DIPG would provide a promising new therapeutic to a pediatric disease which lacks any viable life-saving treatment options and would enable broader clinical use of an immunoconjugate agent for a cell surface target overexpressed in numerous cancer types. Moving an IL13Rα2 ADC to clinical use will require optimizing the antibody binding dynamics and maximizing efficacy of the cytotoxic payload while minimizing peripheral toxicity, optimizations which are the requisite next steps for initiation of an anti-IL13Rα2 ADC clinical trial for DIPG. Fortunately, convectionenhanced delivery (CED) of an antibody is already known to be clinically feasible [3]. Overall, despite the potential limitations of PBD as the cytotoxic payload, anti-IL13Rα2 ADC agents show promise as a therapeutic strategy for an exceptionally intractable disease such as DIPG.
Additional file 1: Figure 1. Cell model response to exploratory immunoconjugate experiments. Cell viability results following a primary antibodysecondary antibody immunoconjugate assay as well as two cytotoxic agents commonly used as ADC payloads. Cytotoxic agents were tested on SF-8628 and DIPG-24. Values in parentheses are IC 50 values. a) Cell viability following two-step incubation of anti-IL13Rα2 primary antibody plus a duocarmycin-conjugated secondary antibody. b) Cell viability following treatment with unconjugated MMAF. c) Cell viability following treatment with unconjugated DM-1.
Additional file 2: Figure 2. Validation of mechanistic function of IL-4 and IL-13 recombinant proteins. Human alveolar rhabdomyosarcoma cell line RH30 was exposed to 20 ng/mL IL-4 or IL-13 recombinant protein for 60 min. STAT6 expression and phosphorylation was detected via western blot to confirm expected activity of recombinant proteins based on previously published studies [26]. Control RH30 demonstrates no phosphorylation of STAT6, while both IL-4 and IL-13 exposure induce STAT6 phosphorylation, as expected.
Additional file 3: Table 1. Table of information, properties, and clinical and genomic characteristics for cell lines used in this study.